2068065-63-2

Usage

Uses

Used in Pharmaceutical Industry:
4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile is used as a building block for the development of new pharmaceutical compounds due to its biological activity and the potential for further functionalization through the bromine substituents. 4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile's reactivity and pharmacological properties, contributed by the cyano group, make it a promising candidate for the synthesis of drugs targeting various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical field, 4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile is utilized as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique structure and reactivity allow for the creation of novel compounds with improved efficacy and selectivity in controlling pests and weeds.
Used in Organic Synthesis:
4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile serves as a versatile intermediate in organic synthesis, particularly for the introduction of functional groups. The presence of bromine atoms facilitates various synthetic transformations, making the compound a valuable precursor for the preparation of a wide range of organic molecules with diverse applications.
Overall, the unique structure and properties of 4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile make it a potentially valuable compound for a variety of applications across different industries, including pharmaceuticals, agrochemicals, and organic synthesis.

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 107-13-1 acrylonitrile 

Downstream Products

• 2152628-33-4 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3.6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 

Relevant academic research and scientific papers

Regioselective Synthesis of Pyrazolo[1,5- a]pyridine via TEMPO-Mediated [3 + 2] Annulation-Aromatization of N-Aminopyridines and α,β-Unsaturated Compounds

A TEMPO-mediated [3 + 2] annulation-aromatization protocol for the preparation of pyrazolo[1,5-a]pyridines from N-aminopyridines and α,β-unsaturated compounds was developed. The procedure offered multisubstituted pyrazolo[1,5-a]pyridines in good to excellent yield with high and predictable regioselectivity. The modification of marketed drugs including Loratadine, Abiraterone, and Metochalcone, and a one-pot three-step gram scale synthesis of key intermediate for the preparation of Selpercatinib were demonstrated. Mechanism studies show that TEMPO serves both as a Lewis acid and as an oxidant.

PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

Pyrazolopyridine derivatives for regulating synthesis activity of estrogen receptor

The invention relates to the technical field of organic chemistry and medicinal chemistry, and in particular, relates to pyrazolopyridine derivatives for regulating the synthesis activity of an estrogen receptor. According to the specific technical scheme, under the alkaline condition, substituted 1-aminopyridine and an alpha,beta-unsaturated compound are stirred together in the presence of an oxidizing agent, and the substituted pyrazol[1,5-a]pyridine compounds are formed. A one-step synthesis strategy is adopted, the alpha,beta-unsaturated compound is used as a raw material, and a series of pyrazol[1,5-a]pyridine compounds are efficiently and highly selectively synthesized in the presence of an organic oxidant.

Aliphatic ring derivatives as RET inhibitors

The invention discloses a series of compounds with aliphatic ring structures and application of the compounds in preparation of RET kinase inhibitors. Specifically disclosed are a compound representedby formula (I), an isomer thereof, or a pharmaceuticall

PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE

In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

FORMULATIONS COMPRISING 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZAB ICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE

6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.